Patent details
93138 Product Name: "rituximab et hyaluronidase humaine recombinante"
Basic Information
- Publication number:
- 93138
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
- EP101834109
- Legal Status:
- Active
- Application number:
- 93138
- First applicant's nationality:
- Procedural language:
- French
Marketing Authorization
- Marketing Authorization Number:
- EU/1/98/067 - C(2014)2048 Mabthera-Rituximab
- Marketing Authorization Type:
- Marketing Authorization Date:
- 26/03/2014
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
Dates
- Filing date:
- 04/07/2016
- First Marketing Authorization date:
- 26/03/2014
- Grant date:
- 05/09/2016
- Activation date:
- 05/03/2024
- Publication date:
- 05/09/2016
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 05/03/2029
- SPC Extension Expiration:
- 05/03/2029
- Rejection date:
- Withdrawal date:
Owner
- From:
- 04/07/2016
- Name:
- Halozyme Inc.
- Address:
- 11388 Sorrento Valley Road, San Diego, CA 92121, United States (US)
Agent
- Name:
- OFFICE FREYLINGER S.A.
- From:
- 04/07/2016
- Address:
- Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
- To:
Inventor
1
- Name:
- Bookbinder Louis
- Address:
- United States (US)
2
- Name:
- Kundu Anirban
- Address:
- United States (US)
3
- Name:
- Frost Gregory
- Address:
- United States (US)
Publication
Bulletin
- Bulletin Heading:
- SPC3
- Bulletin edition number:
- 2025/04
- Publication date:
- 04/03/2025
- Description:
- Section E : Supplementary Protection certificates entered into force – IA publication
Annual Fees
- Annual Fee Due Date:
- 31/03/2026
- Annual Fee Number:
- 23
- Annual Fee Amount:
- 430 Euro
- Expected Payer:
- Last Annual Fee Payment Date:
- 17/03/2025
- Last Annual Fee Paid Number:
- 22
- Last Annual Fee Paid Amount:
- 420 Euro
- Payer:
- Computer Packages INC
| Filing date | Document type | Number of pages |
|---|